Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 4,000 Shares

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $4.75, for a total value of $19,000.00. Following the completion of the transaction, the chief financial officer now owns 34,665 shares in the company, valued at approximately $164,658.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Friday, March 22nd, Mark Leonard Singleton sold 5,541 shares of Bioventus stock. The shares were sold at an average price of $5.39, for a total transaction of $29,865.99.

Bioventus Trading Up 0.2 %

Shares of BVS stock opened at $4.64 on Wednesday. The company’s fifty day simple moving average is $4.96 and its two-hundred day simple moving average is $4.48. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.53 and a quick ratio of 1.01. Bioventus Inc. has a 1 year low of $0.86 and a 1 year high of $6.08. The stock has a market capitalization of $367.35 million, a price-to-earnings ratio of -1.84 and a beta of 0.50.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Bioventus had a negative net margin of 30.49% and a positive return on equity of 2.25%. The business had revenue of $135.42 million for the quarter, compared to analysts’ expectations of $124.84 million. As a group, analysts anticipate that Bioventus Inc. will post 0.16 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Craig Hallum boosted their target price on shares of Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BVS. First Light Asset Management LLC bought a new position in shares of Bioventus in the first quarter worth $12,712,000. Jefferies Financial Group Inc. purchased a new stake in Bioventus during the fourth quarter valued at about $1,460,000. Wasatch Advisors Inc. purchased a new stake in Bioventus during the first quarter valued at about $9,967,000. Western Standard LLC purchased a new stake in Bioventus during the second quarter valued at about $1,145,000. Finally, Jacobs Levy Equity Management Inc. boosted its position in Bioventus by 457.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 366,183 shares of the company’s stock valued at $1,208,000 after buying an additional 300,450 shares during the period. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.